Ignite Creation Date:
2025-12-24 @ 11:54 PM
Ignite Modification Date:
2026-02-20 @ 12:34 PM
Study NCT ID:
NCT01913951
Status:
COMPLETED
Last Update Posted:
2024-05-02
First Post:
2013-07-30
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Vosaroxin and Azacitidine in Treating Patients With Myelodysplastic Syndromes
Sponsor:
Washington University School of Medicine
Organization:
Study Overview
Official Title:
A Phase I Study of Vosaroxin Plus Azacitidine for Patients With Myelodysplastic Syndrome
Status:
COMPLETED
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This phase I trial studies the side effects and the best dose of vosaroxin when given together with azacitidine in treating patients with myelodysplastic syndromes. Drugs used in chemotherapy, such as vosaroxin and azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: